SEC Filing Summary: Predictive Oncology Inc. (POAI)
Business Context and Reporting Period
This Form 8-K Current Report, dated November 25, 2025, covers the results of Predictive Oncology Inc.'s 2025 Annual Meeting of Stockholders. The company is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol POAI. The filing details corporate governance actions, including director elections, auditor ratification, and significant equity plan amendments approved by shareholders.
Key Financial Metrics
The filing text does not provide specific financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes rather than financial results.
Material Changes and Voting Results
Shareholders approved several key proposals at the Annual Meeting. As of the record date, 3,501,430 shares were entitled to vote. The material outcomes include:
- Equity Plan Amendment: Stockholders approved an amendment to the 2024 Equity Incentive Plan, increasing the shares available for issuance by 1,000,000.
- Director Elections: Daniel E. Handley and Chuck Nuzum were elected as Class I directors to serve until the 2028 Annual Meeting. Both received significant support with approximately 1.7 million votes "For" each.
- Warrant Exercise Approval: Shareholders approved the issuance of 14,903,393 shares of common stock upon the exercise of pre-funded warrants, in accordance with Nasdaq Listing Rule 5635(a).
- Auditor Ratification: KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Executive Compensation: The compensation of named executive officers was approved via a non-binding advisory vote.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, or specific risk factors. The document serves as a formal record of the shareholder vote results and the approval of the equity plan amendment. No unusual items or contingencies were disclosed in this specific report.
Investor Verification Checklist
- Verify the impact of the 1,000,000 share increase to the 2024 Equity Incentive Plan on potential future dilution.
- Confirm the final share count and dilution effects resulting from the issuance of 14,903,393 shares via pre-funded warrant exercise.
- Review the full text of the Amendment to the 2024 Equity Incentive Plan filed as Exhibit 10.1 for specific terms.
- Check subsequent filings for the official appointment of the newly elected directors and any changes to the board composition.